Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBT: 2022-2025

Historic EBT for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$39.6 million.

  • Stoke Therapeutics' EBT fell 49.92% to -$39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' EBT is -$39.6 million, which was down 68.74% from -$23.5 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year EBT high stood at $114.2 million for Q1 2025, and its period low was -$39.6 million during Q3 2025.
  • Moreover, its 3-year median value for EBT was -$25.7 million (2024), whereas its average is -$13.0 million.
  • Within the past 5 years, the most significant YoY rise in Stoke Therapeutics' EBT was 532.84% (2025), while the steepest drop was 49.92% (2025).
  • Over the past 4 years, Stoke Therapeutics' EBT (Quarterly) stood at -$25.7 million in 2022, then dropped by 5.07% to -$27.0 million in 2023, then skyrocketed by 60.43% to -$10.7 million in 2024, then slumped by 49.92% to -$39.6 million in 2025.
  • Its EBT was -$39.6 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $114.2 million in Q1 2025.